유방암 액체생검 세계 시장 규모는 2022년에 10억 1,000만 달러로 평가되었고, 2023년 12억 4,000만 달러에서 2031년에는 63억 7,000만 달러로 성장해 예측 기간(2024-2031년)의 CAGR은 22.7%로 성장할 전망입니다.
세계의 유방암 액체생검 시장은 인지도의 향상과 비침습적 진단법의 채용이 박차를 가해 대폭적인 성장을 이루고 있습니다. 반응 모니터링에 필수적인 종양 특이적 유전자 변이, 순환 종양 세포, 무세포 DNA의 검출을 용이하게 합니다. 민감성과 특이성이 향상됨에 따라 시장 확대가 예상됩니다. 전반적으로 기술 혁신과 임상 응용 분야의 융합은 액체생검 시장이 향후 몇 년동안 현저한 성장을 이룰 것으로 보입니다.
Global Breast Cancer Liquid Biopsy Market size was valued at USD 1.01 billion in 2022 and is poised to grow from USD 1.24 billion in 2023 to USD 6.37 billion by 2031, growing at a CAGR of 22.7% during the forecast period (2024-2031).
The global breast cancer liquid biopsy market is witnessing substantial growth, spurred by rising awareness and the adoption of non-invasive diagnostic methods. This innovative technology facilitates the detection of tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA, critical for early diagnosis, treatment selection, and monitoring responses to therapies. As ongoing research and development improve the sensitivity and specificity of liquid biopsy tests, market expansion is anticipated. Collaborative efforts between biotech firms and healthcare institutions, coupled with increasing demand for personalized and targeted breast cancer therapies, are further propelling the market's progression. Overall, the convergence of innovation and clinical application positions the liquid biopsy market for notable growth in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Breast Cancer Liquid Biopsy Market Segmental Analysis
Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Breast Cancer Liquid Biopsy Market
The global breast cancer liquid biopsy market is primarily propelled by the growing demand to effectively tackle breast cancer. The rising use of liquid biopsy methods serves as a key motivator, as these techniques facilitate the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and various biomarkers found in blood samples. This innovation enables healthcare providers to make better-informed treatment choices. Furthermore, liquid biopsies can detect resistance mutations and minimal residual disease, enhancing personalized treatment approaches. As a result, this technology not only improves patient outcomes but also contributes to lowering overall healthcare expenses.
Restraints in the Global Breast Cancer Liquid Biopsy Market
The global breast cancer liquid biopsy market faces several significant restraints, primarily stemming from inadequate investment in healthcare infrastructure. While liquid biopsy tests show considerable promise, their high costs present a substantial barrier to accessibility, particularly for patients with limited financial means or those in areas with poor healthcare funding. The considerable investment required for the development and deployment of advanced liquid biopsy technologies often leads to elevated testing costs, making them less feasible for many individuals. Furthermore, challenges related to reimbursement policies and regulatory approvals hamper widespread adoption, highlighting the critical need to address these financial barriers to enhance equitable access to these crucial diagnostic tools for breast cancer patients worldwide.
Market Trends of the Global Breast Cancer Liquid Biopsy Market
The Global Breast Cancer Liquid Biopsy market is witnessing a significant upward trend, driven by the increasing demand for non-invasive diagnostic methods aimed at early detection and monitoring of breast cancer. As healthcare professionals and patients alike seek alternatives to traditional tissue biopsies, liquid biopsies are gaining traction for their ability to provide timely and accurate genomic insights with minimal discomfort. Technological advancements in assay development and an escalating focus on personalized medicine are further propelling this market. Additionally, rising awareness and supportive regulatory frameworks are fostering a conducive environment for innovation, ultimately driving growth in the breast cancer liquid biopsy sector.